|
M.B. Antsiferov
APPLICATION OF SAXAGLIPTIN AND ITS COMBINATION WITH METFORMIN IN THE THERAPY OF TYPE 2 DIABETES MELLITUS IN ELDERLY PATIENTS
|
№5 / 2016
|
|
I.G. Bakulin, E.V. Vinnytskaya, Yu.G. Sandler, V.A. Keiyan, S.V.Rodionova
ASSESSMENT OF LIVER FIBROSIS IN PATIENTS WITH DIABETES MELLITUS
|
№2 / 2016
|
|
N.A. Demidov (1), S.K. Zakharova (2), A.N. Zavyalov (3)
THE RESULTS OF MONITORING OF THE EFFECTIVENESS AND SAFETY OF RECOMBINANT HUMAN INSULIN PREPARATIONS BIOSULIN R AND BIOSULIN N IN PATIENTS WITH TYPE 2 DIABETES MELLITUS IN CLINICAL PRACTICE
|
№17 / 2015
|
|
A.F. Verbovoy, I.A. Tsanava, N.I. Verdovaya
ADIPOKINES AND HORMONAL AND METABOLIC PARAMETERS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS AND GOUT
|
№17 / 2015
|
|
M.B. Antsiferov (1), T.P. Nikitina (2), A.Yu. Rodionova (3), K.A. Kurbatova (2), T.I. Ionova (2)
HYPOGLYCEMIA AND QUALITY OF LIFE OF PATIENTS WITH TYPE 2 DIABETES MELLITUS
|
№17 / 2015
|
|
G.R. Galstyan
HYPOGLYCEMIC EFFECTS OF FLOZINES COMPARED TO SULFONYLUREA IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
|
№17 / 2015
|
|
A.V. Pashentseva, A.F. Verbovoy
HYPOGLYCEMIC THERAPY AND CARDIOVASCULAR SAFETY
|
№13 / 2015
|
|
M.B. Antsiferov, O.M. Koteshkova
EFFICIENCY OF TRIPLE THERAPY USING LIRAGLUTIDE (VICTOZA) - FIRST LONG-ACTING GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST - IN PATIENTS WITH TYPE 2 DIABETES MELLITUS AND VISCERAL OBESITY
|
№5 / 2015
|
|
A.S. Ametov
ADVANTAGES OF FIXED COMBINATION OF SAXAGLIPTIN AND METFORMIN WITH MODIFIED RELEASE (KOMBOGLYCE PROLONG) IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS
|
№5 / 2015
|
|
N.A. Chernikova, L.P. Ivanova, F.T. Abaeva
ADVANTAGES OF TIMELY INITIATION OF INSULIN THERAPY. RESULTS OF THE RUSSIAN OBSERVATIONAL PROGRAM HUBIN
|
№5 / 2015
|
|
A.M. Mkrtumyan
ALOGLIPTIN – EFFECTIVE AND SAFE DIPEPTIDYL PEPTIDASE-4 INHIBITOR IN THE THERAPY OF TYPE 2 DIABETES MELLITUS
|
№5 / 2015
|
|
T.Yu.Demidova
SGLT 2INHIBITORS: PHARMACOLOGICAL GLYCOSURIA AS A NEW APPROACH TO THE MANAGEMENT OF TYPE 2 DIABETES MELLITUS
|
№5 / 2015
|
Русский
